|
Gene: AR |
Gene summary for AR |
Gene summary. |
Gene information | Species | Human | Gene symbol | AR | Gene ID | 367 |
Gene name | androgen receptor | |
Gene Alias | AIS | |
Cytomap | Xq12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P10275 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
367 | AR | GSM4909282 | Human | Breast | IDC | 8.07e-06 | -1.87e-01 | -0.0288 |
367 | AR | GSM4909285 | Human | Breast | IDC | 8.07e-06 | -1.82e-01 | 0.21 |
367 | AR | GSM4909286 | Human | Breast | IDC | 1.72e-05 | -1.87e-01 | 0.1081 |
367 | AR | GSM4909287 | Human | Breast | IDC | 2.91e-04 | -1.82e-01 | 0.2057 |
367 | AR | GSM4909290 | Human | Breast | IDC | 3.95e-05 | 3.05e-01 | 0.2096 |
367 | AR | GSM4909291 | Human | Breast | IDC | 8.28e-03 | -1.87e-01 | 0.1753 |
367 | AR | GSM4909293 | Human | Breast | IDC | 2.02e-73 | 1.07e+00 | 0.1581 |
367 | AR | GSM4909298 | Human | Breast | IDC | 4.69e-05 | 1.52e-01 | 0.1551 |
367 | AR | GSM4909301 | Human | Breast | IDC | 2.32e-27 | 7.04e-01 | 0.1577 |
367 | AR | GSM4909303 | Human | Breast | IDC | 1.07e-07 | 5.92e-01 | 0.0438 |
367 | AR | GSM4909306 | Human | Breast | IDC | 1.70e-27 | 6.27e-01 | 0.1564 |
367 | AR | GSM4909307 | Human | Breast | IDC | 5.11e-04 | 2.83e-01 | 0.1569 |
367 | AR | GSM4909308 | Human | Breast | IDC | 3.47e-09 | 3.55e-01 | 0.158 |
367 | AR | GSM4909309 | Human | Breast | IDC | 1.10e-02 | -1.66e-01 | 0.0483 |
367 | AR | GSM4909311 | Human | Breast | IDC | 9.12e-06 | -8.10e-02 | 0.1534 |
367 | AR | GSM4909313 | Human | Breast | IDC | 2.86e-05 | 3.06e-01 | 0.0391 |
367 | AR | GSM4909319 | Human | Breast | IDC | 5.65e-03 | -1.17e-01 | 0.1563 |
367 | AR | M5 | Human | Breast | IDC | 2.93e-07 | 7.39e-01 | 0.1598 |
367 | AR | P1 | Human | Breast | IDC | 2.51e-02 | 9.14e-02 | 0.1527 |
367 | AR | NAFLD1 | Human | Liver | NAFLD | 8.87e-12 | 1.11e+00 | -0.04 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00101712 | Skin | AK | body morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:00604436 | Skin | AK | mammary gland morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:19021175 | Skin | AK | positive regulation of organelle assembly | 16/1910 | 67/18723 | 9.32e-04 | 7.56e-03 | 16 |
GO:00603233 | Skin | AK | head morphogenesis | 10/1910 | 32/18723 | 9.35e-04 | 7.56e-03 | 10 |
GO:0071103 | Skin | AK | DNA conformation change | 47/1910 | 290/18723 | 9.43e-04 | 7.61e-03 | 47 |
GO:001407419 | Skin | AK | response to purine-containing compound | 28/1910 | 148/18723 | 9.46e-04 | 7.63e-03 | 28 |
GO:00518977 | Skin | AK | positive regulation of protein kinase B signaling | 24/1910 | 120/18723 | 9.53e-04 | 7.64e-03 | 24 |
GO:003133325 | Skin | AK | negative regulation of protein-containing complex assembly | 27/1910 | 141/18723 | 9.56e-04 | 7.66e-03 | 27 |
GO:003032410 | Skin | AK | lung development | 32/1910 | 177/18723 | 9.60e-04 | 7.68e-03 | 32 |
GO:007097219 | Skin | AK | protein localization to endoplasmic reticulum | 17/1910 | 74/18723 | 1.04e-03 | 8.19e-03 | 17 |
GO:00075658 | Skin | AK | female pregnancy | 34/1910 | 193/18723 | 1.09e-03 | 8.48e-03 | 34 |
GO:000223720 | Skin | AK | response to molecule of bacterial origin | 56/1910 | 363/18723 | 1.10e-03 | 8.60e-03 | 56 |
GO:005170215 | Skin | AK | biological process involved in interaction with symbiont | 20/1910 | 94/18723 | 1.11e-03 | 8.63e-03 | 20 |
GO:012003219 | Skin | AK | regulation of plasma membrane bounded cell projection assembly | 33/1910 | 186/18723 | 1.13e-03 | 8.75e-03 | 33 |
GO:005105418 | Skin | AK | positive regulation of DNA metabolic process | 35/1910 | 201/18723 | 1.14e-03 | 8.83e-03 | 35 |
GO:00603243 | Skin | AK | face development | 12/1910 | 44/18723 | 1.16e-03 | 8.88e-03 | 12 |
GO:004308716 | Skin | AK | regulation of GTPase activity | 54/1910 | 348/18723 | 1.17e-03 | 8.98e-03 | 54 |
GO:190374710 | Skin | AK | regulation of establishment of protein localization to mitochondrion | 13/1910 | 50/18723 | 1.19e-03 | 9.11e-03 | 13 |
GO:000808816 | Skin | AK | axo-dendritic transport | 17/1910 | 75/18723 | 1.22e-03 | 9.32e-03 | 17 |
GO:001003828 | Skin | AK | response to metal ion | 57/1910 | 373/18723 | 1.26e-03 | 9.52e-03 | 57 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052159 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
hsa0521514 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
GZMA | PARD3 | GZMA_PARD3 | PARs | Breast | ADJ |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | DCIS |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | Healthy |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | IDC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | ADJ |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | Cervix | CC |
CTSG | PARD3 | CTSG_PARD3 | PARs | Cervix | CC |
GZMA | PARD3 | GZMA_PARD3 | PARs | Cervix | CC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | CC |
C5 | C5AR1 | HC_C5AR1 | COMPLEMENT | Cervix | CC |
EDA | EDAR | EDA_EDAR | EDA | Cervix | CC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | Precancer |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | AD |
CTSG | PARD3 | CTSG_PARD3 | PARs | CRC | AD |
GZMA | PARD3 | GZMA_PARD3 | PARs | CRC | AD |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | ADJ |
CTSG | PARD3 | CTSG_PARD3 | PARs | CRC | ADJ |
GZMA | PARD3 | GZMA_PARD3 | PARs | CRC | ADJ |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | CRC |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
AR | SNV | Missense_Mutation | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
AR | SNV | Missense_Mutation | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | QUININE SULFATE | QUININE SULFATE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | NILUTAMIDE | NILUTAMIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | ARN-509 | APALUTAMIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | CRUFOMATE | CRUFOMATE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | 2-AMINOFLURENE | CHEMBL84472 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 |